montelukast as an add-on drug in induced azotemia in humans following gastroenteritis

Background: gastroenteritis, as a rare and heterogeneous condition, is characterized by patchy or diffuse infiltration of gastrointestinal tissue. induced azotemia in humans following gastroenteritis has been evaluated in some studies. objectives: the aim of present study was to evaluate the effect of montelukast on induced azotemia in humans following gastroenteritis. methods: this study examined children with gastroenteritis with moderate dehydration and more than 3 years of age. the cases had a glomerular filtration rate (gfr) less than 90 and were evaluated in two groups of control (n = 20) and intervention (n = 20). montelukast (5-mg tablets) was given to patients in the intervention group for 5 days. normal saline at a rate of 20 cc/kg was given to both groups within 20 minutes until clinical symptoms improved. finally, the improvement of renal function was evaluated and compared between the 2 groups using spss. results: out of 40 evaluated patients, the mean age of the control and intervention groups was 5.52 and 5.15 years, respectively. also, 13 cases (65.0%) in the control group and 9 cases (45.0%) in the control group were males. the mean creatinine (cr) was significantly reduced after treatment in the intervention group (p = 0.001). also, the mean gfr after treatment was significantly higher in the intervention group (p = 0.001), and gfr improvement duration was significantly lower in the intervention group (p = 0.002). conclusions: montelukast as an add-on drug was effective in reducing the time of gfr enhancement; thus, we can consider it as an add-on drug in azotemia.